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Abstract
Background There are indications that obesity and hyperuri-
cemia may influence the formation and composition of uri-
nary stones. The aim of our study was to determine the effect
of obesity and hyperuricemia on the urinary lithogenic risk
profile in a large cohort of pediatric patients.
Methods The study population comprised 478 children with
urolithiasis and 517 healthy children (reference group). We
studied the effects of obesity on the lithogenic profile by
dividing the patients with urolithiasis into two groups based
on body mass index Z-score (patients who were overweight/
obese vs. those with normal weight for age) and comparing
the two groups. To study the effect of hyperuricemia on the
lithogenic profile, we divided the patients with urolithiasis
into two groups based on the presence or not of hyperuricemia
(110 patients with urolithiasis accompanied by hyperuricemia
vs. 368 patients with urolithiasis and normal serum uric acid
levels) and compared the groups.
Results Among the children and adolescents with urolithiasis
and hyperuricemia, there was a significantly lower excretion
of crystallization inhibitors (citrates, magnesium). We also
found significantly negative correlations between serum uric
acid levels and the urine citrate/creatinine ratio (citrate/cr.;
r=−0.30, p<0.01), as well as the magnesium/cr. ratio
(Mg/cr.; r=−0.33, p<0.01). There was no statistically signif-
icant differences in the urinary excretion of oxalates, citrates,
calcium, phosphorus, magnesium and uric acid between chil-
dren with urolithiasis who were either overweight or obese
and children with urolithiasis who had a normal body weight.
Conclusions In our pediatric patient cohort, hyperuricemia
was associated with a decrease in the excretion of crystalliza-
tion inhibitors in the urine, but the clinical relevance of this
observation needs to be confirmed in future studies. Obesity
and overweight had no direct influence on the lithogenic risk
profile in the urinary stone formers in our study, but there was
an indication that higher serum uric acid may be associated
with impairment in renal function, which in turn could influ-
ence the excretion of lithogenic parameters.
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Introduction
The incidence of urolithiasis in children, which is associated
with considerable morbidity and recurrence, has increased
significantly during the past few decades. The prevalence of
pediatric urolithiasis is estimated to be 1–5 % and to account
for about 1 in 1,000 pediatric hospital admissions in the USA
[1, 2]. Recent studies conducted in major pediatric centers in
the USA have observed that the incidence of urolithiasis in
children is increasing [3]. The etiology of urolithiasis in chil-
dren is largely unknown, and this increasing incidence has
been attributed to many factors, such as metabolic, anatomi-
cal, dietary and environmental risk factors [4–8].
One proposal is that the increase in stone disease is due to
an increased consumption of salty fast foods or high-protein
diets, an increasingly sedentary lifestyle, the global rise in
obesity, global warming and climate changes [9]. Although
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in pediatric patients, infection is considered the primary cause
of urolithiasis [10, 11] the etiologic paradigm for urolithiasis
in children has shifted from predominantly infectious to met-
abolic causes [12–15]. Studies over the past few decades have
identified metabolic disorders in 33–95% of pediatric patients
with urolithiasis. Many studies have outlined the systematic
detection of metabolic risk factors—such as hypercalciuria,
cystinuria and hyperoxaluria—in children with urolithiasis
[16–19].
Recent epidemiologic studies have shown an increased
prevalence of kidney stones in patients with metabolic syn-
drome and lifestyle-related diseases, such as obesity [20], type
2 diabetes [21] and hypertension [22, 23]. There is supporting
evidence that uric acid may play a pathogenic role in meta-
bolic syndrome, with numerous studies reporting an associa-
tion between elevated serum uric acid and obesity [24, 25].
Although the question of whether obesity may influence the
formation and composition of stones has been studied, far too
little attention has been paid to this problem in children and
teenagers.
The aims of this study were, first, to investigate the urinary
lithogenic risk profile in children and adolescents with uro-
lithiasis and, secondly, to determine whether obesity or hy-
peruricemia influences the excretion of electrolytes in the
urine.
Material and methods
This observational cross-sectional prospective study was un-
dertaken in the Department of Pediatric Nephrology, Univer-
sity Children’s Hospital in Bialystok between 2002 and 2013.
The patient group consisted of 478 children and adolescents,
aged 3–18 (median 14.79 years) years with urinary stones of
different composition. Most of the patients presented with
typical renal colic or stone passage, however about 25 % were
asymptomatic or diagnosed with erythrocyturia. In all cases,
urolithiasis was confirmed by ultrasonography, and in about
60 % of the cases, also by X-ray examination.
The exclusion criteria included acute infection and inade-
quate 24 h urine collection as assessed by the level of urine
creatinine (cr.) excretion (normal 15–25 mg/kg/24 h). Patients
treated with any medications known to affect serum uric acid
levels and electrolyte excretions were also excluded.
The reference group comprised 517 healthy children and
adolescents, aged 3–18 (median 14.59 years) years, with
normal urinary excretion levels of citrate, calcium, oxalate
and uric acid and without abnormalities in dipstick urinalysis
(Bayer Diagnostic, Bridgend, UK). These children and ado-
lescents were mainly volunteers with a past history of primary
nocturnal enuresis (65 %), who were not treated with any
drugs at the moment of the study, or of inguinal hernia
(25 %) who had been approached to participate while
attending the academic center or the children of hospital staff.
None of the controls reported a family history of urolithiasis,
while their recent screening based on ultrasonography exclud-
ed urinary stones.
The group of children and adolescents with urolithiasis was
subsequently divided into two subgroups: (1) urolithiasis
HU(+) consisting of patients with urolithiasis accompanied
by hyperuricemia (serum uric acid levels ≥5.5 mg/dL); (2)
urolithiasis HU(−), i.e. patients with urolithiasis and normal
serum uric acid levels (<5.5 mg/ dL). In addition, we analyzed
the results by dividing patients with urolithiasis in two sub-
groups according to body mass index (BMI) Z-score: (1)
subjects with urolithiasis and overweight or obesity ( BMI
Z-score ≥1) and (2) subjects with urolithiasis and normal body
weight (BMI Z-score <1).
For all participants, careful clinical histories were taken and
physical examinations were performed. Body weight and
height were measured using a balance beam scale and pediat-
ric wall-mounted stadiometer, respectively, and BMI was
calculated as weight (in kilograms) divided by the square of
height (meters squared). Age- and height-specific reference
values for BMI and height were generated by the least mean
squares (LMS) method [26], which characterizes the distribu-
tion of a variable by its median (M), the coefficient of varia-
tion (S, i.e., the ratio of the standard deviation and mean), and
skewness (L) required to transform the data to normality.
Evaluation of these parameters is obtained by a maximum-
likelihood curve-fitting algorithm to the original data plotted
over the independent variable. The formula for calculating the
Z-score of BMI or height was: LMS − SDS={[YM(t)]L(t) −
1}/[L(t) × S(t)], where SDS is the standard deviation score, Y
is the individual observation and L(t), M(t), and S(t) are the
specific values of L, M and S interpolated for the child’s age
and gender. The LMS values were taken from the OLAF study
published by Kulaga et al. [27]. After an overnight fasting,
5 ml of venous, peripheral blood was collected from each
patient and used as a reference for routine laboratory testing.
Isolated serum aliquots were stored at −80 °C for further
analysis. The biochemical work-up included serum creatinine,
urea, fasting plasma glucose, lipid profile and, serum uric acid
concentration.
Serum creatinine concentration was determined by the
Jaffe reaction, and uric acid level was assessed using the
colorimetric method, both on a Hitachi apparatus. Serum
cholesterol levels were determined by the enzymatic
method on the Roche Hitachi 912 chemistry analyzer
(Roche Diagnostics, Mannheim, Germany). Serum glu-
cose was measured with the Integra 800 chemistry ana-
lyzer (Roche Diagnostics). We calculated fractional ex-
cretion of uric acid (FEUA) using the conventional equa-
tions: [(urineuricacid × serumcr.)/(urinecr.× serum uric
acid) × 100]. FEUA was expressed as a percentage.
Glomerular filtration rate (GFR) was assessed using the
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updated Schwartz’s formula (GFR), which is recom-
mended in the pediatric population. The estimated GFR
(eGFR) was calculated from the Schwartz formula: eGFR
(ml/min/1.73 m2) = 0.413 × growth (cm)/ serum cr.
(mg/dL).
All study subjects were evaluated using the same standard
protocol which also included the request to continue to follow
their customary diet. During the 24-h urine collection, urine
was stored in sterile, closed containers at 4 °C without the
addition of preservatives, and all measurements were conduct-
ed within 4 h after the end of the collection period. Urine
citrate concentrations were determined by an enzymatic meth-
od using a commercial system (Boehringer Mannheim/R-
Biopharm, Darmstadt, Germany) and adjusted for creatinine.
Urine calcium (Ca) and creatinine were assessed using the
Cobar-Integra 800 analyzer and Roche reagents (Roche Diag-
nostics). We also analyzed the urine Ca/citrate ratio, which is a
age-independent parameter [28]. Urine oxalate levels were
examined using standard enzymatic–spectrophotometric
methodology (product nr. 591D; Trinity Biotech, Berkeley
Heights, NJ). Urinary pH was determined using a microcom-
puter pHmeter (model CP-315M; Elmetron, Zabrze, Poland).
The Bonn Risk Index (BRI) is a measure of the risk for urinary
calcium oxalate (CaOx) stone formation and was determined
according to the method of Laube [29], using a modified
analytical system described elsewhere [30]. In brief, after the
urinary Ca2+ content was determined, the urine was titrated
step-by-step with Ox2- on a computer-operated analytical
system. At the moment crystallized particles of CaOx caused
a 2 % decrease in light transmission, the computer application
automatically stopped the titration process. The BRI value
was then calculated as BRI=Ca2+::Ox2-. Renal ultrasonogra-
phy was carried out using a high-resolution ultrasound ma-
chine (Toshiba SSH-140A; probe Convex 3.75 MHz;
Toshiba, Tokyo, Japan) by a trained person.
The protocol was approved by the Bioethics Committee of
The Medical University of Bialystok in accordance with the
Declaration of Helsinki. Informed consent was obtained from
the parents of all participants and children older than 16 years
of age.
Statistical analysis
Statistical analyses were performed using Statistica®, ver.
10.0 PL (StatSoft, Tulsa, OK). Each of the two groups was
compared using the chi-square and Fisher exact tests for
categorical variables and the t test for continuous variables
for normally distributed data and the Mann–Whitney test for
the data not normally distributed. The correlations were made
with Spearmans’ test. A p value of <0.05 was considered to be
statistically significant.
Results
The comparisons of demographic, clinical and metabolic
data between the urolithiasis and reference group are
summarized in Table 1. The median age, body height,
weight and BMI Z-score did not differ between groups.
Biochemical studies showed that the urolithiasis group
had higher cholesterol levels than the reference group.
The urine excreted by our patients with urolithiasis also
contained lower levels of citrate (p<0.01), significantly
higher levels of oxalate and Ca corrected for urinary
creatinine and had a significantly higher Ca/citrate ratio
and BRI (p<0.01).
Data on the subgroup analyses are shown in Table 2. .
Ninety-seven subjects with urolithiasis (20.29 %) were clas-
sified as overweight or obese. Of those, 76 were found to be
overweight with a BMI Z-score of ≥1 and <2, and 21 were
obese with a BMI Z-score ≥2. The median serum uric acid
concentration in the subgroup of patients with urolithiasis and
a BMI Z-score of ≥1 was significantly higher than that of the
subgroup of patients with urolithiasis and a normal body
weight {4.98 [interquartile range (IQR) 4.29–5.84] vs. 4.43
(IQR 3.82–5.21) mg/ dL, respectively; p<0.01}. No statisti-
cally significant differences between these subgroups were
found for urinary excretion of oxalates, citrates, calcium,
phosphorus, magnesium and uric acid.
The correlation analyses of BMI Z-score with clinical
parameters (Table 3) revealed that the BMI Z-score was pos-
itively correlated with serum uric acid (r=0.14, p<0.01) and
creatinine (r=0.12, p<0.01) and negatively correlated with
eGFR (r=−0.13, p<0.01). However, there were no significant
correlations between the BMI Z-score and urinary lithogenic risk
profile. We also found that the BMI was negatively correlated
with urine pH (r=−0.1, p<0.01), but we didn’t find statistically
significant correlations between BMI Z-score and urine pH.
Those children and adolescents with urolithiasis and hy-
peruricemia had a significantly lower excretion of most elec-
trolytes corrected for urinary creatinine, especially crystalliza-
tion inhibitors (citrates, magnesium) (Table 4 ). The FEUA
has been observed to be lower in patients with hyperuricemia
than in those with normouricemia, supporting the notion that
the predominant mechanism for hyperuricemia is renal
underexcretion of uric acid. Therefore, we also analyzed the
relationship between serum uric acid levels and urinary crys-
tallization rates and found significantly negative correlations
between serum uric acid levels and the citrate/cr. (r=−0.30,
p<0.01) and Mg/cr. (r=−0.33, p<0.01) ratios. In reference
patients with elevated uric acid we also found a lower urine
excretion of citrate and magnesium. These results are summa-
rized in Table 5. Similarly, significant differences were found
in the urinary excretion of oxalates, citrates, calcium, phos-
phorus, magnesium and uric acid between the reference pa-
tients with hyperuricemia and normouricemia (p<0.01).
Pediatr Nephrol (2015) 30:797–803 799
Discussion
The present study was designed to determine the effect of
obesity and metabolic disturbances on the urinary lithogenic
risk profile in a large cohort of pediatric patients. In the first
analysis, we confirmed that in comparison to the healthy
children and adolescents of the reference group, the patients
with urolithiasis had hypocitraturia, hypercalciuria and
hyperoxaluria, as well as an increased BRI. This result is in
agreement with published data. Many large epidemiologic
studies have demonstrated that hypercalciuria is the most
common metabolic abnormality in children with urolithiasis
[31, 32]. Other studies have indicated that approximately 2–
36% of patients with pediatric urolithiasis have hyperoxaluria
Table 1 Anthropometric, clinical
and metabolic characteristics of
the patient group (patients with
urolithiasis) and reference group
Data are presented as the median
with the interquartile range [IQR;
Q1 (lower quartile) andQ3 (upper
quartile)] in parenthesis, unless
otherwise indicated
BMI, Body mass index; GFR,
glomerular filtration rate; BRI,
Bonn Risk Index; cr., creatinine;
Mg, magnesium; P, phosphorus;
NS, not significant a The chi-








Age (years) 14.59 (10.64–16.60) 14.79 (11.14–16.74) NS
Gender, n (female/male) 298/ 219 273/ 205 NSa
BMI (kg/ m2) 19.49 (17.01–22.02) 19.36 (16.87–22.04) NS
BMI Z-score 0.08 (−0.56–0.79) 0.03 (−0.65–0.83) NS
Urine volume (mL/kg/24 h) 19.70 (13.90–27.19) 21.26 (14.81–29.17) <0.05
Creatinine (mg/dL) 0.595 (0.47–0.71) 0.60 (0.48–0.73) NS
Uric acid (mg/dL) 4.52 (3.83–5.47) 4.53 (3.89–5.32) NS
Urea (mg/dL) 25 (21–29) 25 (21–30) NS
Cholesterol (mg/dL) 151.5 (137–170) 161 (138–186) <0.01
BRI (L−1) 0.30 (0.12–0.80) 0.96 (0.14–3.76) <0.01
Urine pH 6.36 (6.03–6.70) 6.33 (6.03–6.60) NS
GFR (ml/min/1.73 m2) 125.07 (110.49–143.52) 123.60 (102.21–144.23) NS
Oxalate/cr. (mmol/g cr.) 0.28 (0.19–0.37) 0.46 (0.23–0.69) <0.01
Citrate/cr. (mg/g cr.) 585.10 (482.18–810) 461.13 (277.64–702.18) <0.01
Ca/cr. (mmol/g cr.) 2.87 (2.16–3.65) 3.53 (2.07–5.86) <0.01
P/cr. (mmol/g cr.) 20.36 (16.73–25.45) 19.61 (15.47–26) NS
Mg/cr. (mmol/g cr.) 3.47 (2.98–4.11) 3.32 (2.59–4.37) NS
Uric acid/cr. 0.43 (0.36–0.53) 0.44 (0.36–0.57) NS
Ca/citrate 0.18 (0.13–0.24) 0.32 (0.17–0.59) <0.01
Table 2 Metabolic characteris-
tics of patients with urolithiasis
and overweight or obesity (BMI
Z-score ≥1) and with urolithiasis
and a normal body weight (BMI
Z-score <1)
Data are presented as the median
with the IQR in parenthesis, un-
less otherwise indicated
a The chi-square statistic was used
Demographic and metabolic
characteristics
Urolithiasis group with BMI
Z-score ≥1 (n = 97)
Urolithiasis group with BMI
Z-score <1 (n = 381)
p
Age (years) 14.27 (11.51–16.43) 14.89 (11.14–16.85) NS
Gender, n (female/male) 53/44 221/160 NSa
Urine volume (ml/kg/24 h) 18.07 (12.50–23.15) 22.58 (15.84–30.00) <0.01
Creatinine (mg/dL) 0.60 (0.49–0.73) 0.60 (0.48–0.73) NS
Uric acid (mg/dL) 4.98 (4.29–5.84) 4.43 (3.82–5.21) <0.01
Cholesterol (mg/dL) 171 (151–187) 154.5 (135–185) NS
Glucose (mg/dL) 90 (85–93) 88 (83–93) NS
BRI (L−1) 0.66 (0.14–3.01) 1.13 (0.15–3.87) NS
Urine pH 6.40 (6.00–6.61) 6.33 (6.05–6.60) NS
GFR (ml/min/1.73 m2) 126.46 (104.41–145.78) 122.66 (100.64–143.67) NS
Oxalate/cr. (mmol/g cr.) 0.38 (0.24–0.65) 0.47 (0.23–0.71) NS
Citrate/cr. (mg/g cr.) 461.86 (267.16–713.51) 455.99 (278.10–697.4) NS
Ca/cr. (mmol/g cr.) 2.77 (1.84–5.48) 3.63 (2.12–5.89) NS
P/cr. (mmol/g cr.) 19.63 (15.27–25.10) 19.61 (15.54–26.02) NS
Mg/cr. (mmol/g cr.) 3.13 (2.43–4.04) 3.39 (2.62–4.53) NS
Uric acid/cr. 0.44 (0.35–0.56) 0.44 (0.36–0.57) NS
Ca/citrate 0.28 (0.15–0.56) 0.32 (0.17–0.59) NS
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[33–35] and that there is a large prevalence of hypocitraturia
in patients with urolithiasis, ranging from 8 to 68.3 % [36]. It
is interesting to note that in our study we were able to dem-
onstrate that serum cholesterol level in the urolithiasis group
was significantly higher than that in the reference group.
These findings are consistent with those of recent studies
reporting associations between kidney stones and traditional
atherosclerotic risk factors, including dyslipidemia and obesi-
ty [20, 37].
The second analysis was designed to test our hypothesis
that children and adolescents with urinary stones and an
increased BMI Z-score (overweight/obese) have different uri-
nary risk lithogenic profiles than patients with urolithiasis and
a normal body weight. However, contrary to expectations, we
did not find a significant difference between these two groups.
Little is known about the biochemical mechanisms that
would explain the association between obesity and urolithia-
sis. Recent studies have demonstrated that an increased body
weight is related with changes in the biochemical components
of urine, including phosphate, oxalate, uric acid and citrate
[38–41]. Negri et al. [40] reported that uric acid and oxalate
were significantly higher in the urine samples of obese pa-
tients, and Taylor et al. [42] showed a positive relationship
between BMI and urinary excretion of oxalate, calcium, uric
acid, citrate, sodium, phosphate and potassium. However
these studies only demonstrated that obese patients are more
predisposed to urolithiasis than those within the normal
weight range. In our study we also confirmed that obese
patients with urolithiasis had more hypocitraturia and
hyperoxaluria than the reference group—although we found
no such differences between the former group and urinary
stone patients of normal weight. One possible explanation is
that our patients were not extremely obese, with most being
clinically overweight (n=76) and only 21 patients being clin-
ically obese. Powell et al. [41] demonstrated that patients with
urolithiasis who weighed more than 120 kg excreted more
oxalate, calcium and uric acid in than urine than patients
weighing less than 100 kg. Similarly, Semins et al. [38]
demonstrated that only significant obesity (BMI>30 kg/m2)
was associated with a significantly greater likelihood of being
diagnosed with a kidney stone. In another study in adult stone
Table 3 Correlations between BMI Z-score and serum uric acid level and
examined parameters
Metabolic parameters BMI Z-score Uric acid (mg/dL)
r p r p
Uric acid (mg/dL) 0.14 <0.01* – –
Creatinine (g/24 h) 0.12 <0.01* 0.50 <0.01
Urine pH −0.001 NS −0.10 <0.01
eGFR (mL/min/1.73 m2) −0.13 <0.01* −0.16 <0.01
Citrate/cr. (mg/g cr.) −0.002 0.94 −0.30 <0.01
Mg/cr. (mmol/g cr.) −0.04 0.23 −0.33 <0.01
Oxalate/cr. (mmol/g cr.) −0.02 0.52 −0.16 <0.01
Ca/cr. (mmol/g cr.) −0.03 0.31 −0.13 <0.01
P/cr. (mmol/g cr.) −0.04 0.20 −0.31 <0.01
Uric acid/cr. −0.02 0.61 −0.37 <0.01
Ca/citrate −0.00 0.99 0.13 <0.05
eGFR, Estimated glomerular filtration rate; Ca, calcium
Table 4 Metabolic characteris-
tics of patients with urolithiasis
and hyperuricemia and patients
with urolithiasis and
normouricemia
Data are presented as the median
with the IQR in parenthesis, un-
less otherwise indicated
HU+, hyperuricemia; HU− ,
normouricemia








Age, n (years) 16.29 (14.93–17.35) 14.24 (9.95–16.48) <0.01
Gender, n (female/male) 34/76 239/129 <0.05a
BMI Z-score 0.37 (−0.33–1.14) −0.06 (−0.72–0.67) <0.01
Urine volume (mL/kg/24 h) 19.38 (11.76–23.81) 22.04 (15.69–30.00) <0.01
Creatinine (mg/dL) 0.78 (0.65–0.85) 0.56 (0.45–0.67) <0.01
Cholesterol (mg/dL) 155 (138–188) 171 (143–185.5) NS
Glucose (mg/dL) 90 (83–93) 88 (84–93) NS
BRI (L−1) 0.94 (0.08–4.16) 1.01 (0.16–3.89) NS
Urine pH 6.28 (5.92–6.50) 6.34 (6.08–6.61) NS
GFR (mL/min/1.73 m2) 122.32 (104.83–134.97) 125.42 (100.95–149.22) NS
Oxalate/cr. (mmol/g cr.) 0.41 (0.17–0.60) 0.49 (0.26–0.73) <0.01
Citrate/cr. (mg/g cr.) 291.94 (189.80–420.99) 502.75 (317.30–767.81) <0.01
Ca/cr. (mmol/g cr.) 3.24 (1.45–5.38) 3.66 (2.20–5.92) <0.05
P/cr. (mmol/g cr.) 16.51 (13.75–20.47) 20.77 (16.38–26.82) <0.01
Mg/cr. (mmol/g cr.) 2.78 (2.11–3.45) 3.52 (2.67–4.62) <0.01
Uric acid/cr. 0.36 (0.31–0.43) 0.46 (0.37–0.59) <0.01
Ca/citrate 0.41 (0.20–0.78) 0.30 (0.16–0.56) <0.05
Fractional excretion of uric acid (%) 4.02 (3.60–4.94) 6.08 (5.04–7.60) <0.01
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formers Taylor et al. [42] found a positive association between
BMI and urinary oxalate excretion in women, and with uri-
nary calcium excretion in men.
It has been proposed that an increase in BMI causes a
significant decrease in urinary pH level [42]. We confirmed
this proposal in our study. Maalouf et al. [43] found that in
urinary stone patients, urinary pH had a strong graded inverse
association with BMI. In contrast, Nouvenne et al. [44] re-
ported that among their study population there was no signif-
icant change in urinary pH with increasing BMI in both
patients with urolithiasis and the healthy control group. The
underlying factors explaining the fall in urine pHwith increas-
ing BMI in urolithiasis patients is not yet well explained. One
possible explanation could be insulin resistance [45] as it has
been proposed that hyperinsulinemia could lead to decreased
urinary citrate level as well as increased levels of lithogenic
factors in urine, including calcium, uric acid and oxalate [39,
45, 46]. In contrast, in their study, Dwyer et al. [47] did not
observe significant trends in obesity in adolescent stone-for-
mers. In a similar large-scale study, Penido et al. [48] also
demonstrated that the incidence of obesity in pediatric patients
with urolithiasis was not higher than that in the general pop-
ulation. Similar observations were reported by Kieran et al.
[49] who described that an increased BMI did not correlate
with earlier stone development, large stones or the need for
multiple procedures in a stone-forming population.
We noted that our patients were indeed hyperuricemic, but
that uric acid excretion did not differ between patients with
urolithiasis and overweight or obesity and with urolithiasis
and a normal body weight.
During our study we noticed that hyperuricemia—but not
the BMI Z-score—influenced the urinary lithogenic risk pro-
file in pediatric patients with urolithiasis. After taking serum
uric acid levels into account, we extended our observation by
showing that there was a significant decrease of crystallization
inhibitors in hyperuricemic children and adolescents. It is
interesting to note that we found a significant correlation
between serum uric acid level and the urinary excretion of
citrates and magnesium, which to our knowledge is the first
observation of such a relationship.
The influence of dietary habits on urinary stone formation
has been widely reported in the literature. It would appear that
the consumption of animal protein predisposes to the devel-
opment of hyperuricemia, thereby creating an acid load,
which increases the urinary excretion of calcium and uric acid
and reduced citrate [50].
A limitation of this study was the relatively small sample size
of obese and overweight patients, when compared to those of
normalweight. Similarly, therewas a disproportion in the numbers
of patients with hyperuricemia and those with normouricemia.
Further work needs to be done in patients with hyperuricemia, but
without urinary stones, to establish whether they are predisposed
to urolithiasis and, if so, how it can be prevented.
In conclusion, hyperuricemia is associated with a decrease
in the excretion of crystallization inhibitors in the urine. How-
ever, the clinical relevance of this observation needs to be
confirmed in further studies. Among our patient cohort, obe-
sity and overweight had no direct influence on the lithogenic
risk profile in urinary stone formers, However it is possible
that higher serum levels of uric acid were associated with
impairment in renal function, which in turn could influence
the excretion of lithogenic parameters.
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reproduction in any medium, provided the original author(s) and the
source are credited.
References
1. Rizvi SA, Naqvi SA, Hussain Z, Hashmi A, Hussain M, Zafar MN,
Sultan S, Mehdi H (2002) Pediatric urolithiasis: developing nation
perspectives. J Urol 168:1522–1525
2. Marx JA, Hockberger S, Walls RM (eds) (2002) Rosen’s emergency
medicine: concepts and clinical practice, 5th edn. Mosby, St. Louis
3. Kroovand RL (1997) Pediatric urolithiasis. Urol Clin North Am 24:
173–184
4. Clayton DB, Pope JC (2011) The increasing pediatric stone disease
problem. Ther Adv Urol 3:3–12
5. Edvardsson V, Elidottir H, Indridason OS, Palsson R (2005) High
incidence of kidney stones in Icelandic children. Pediatr Nephrol 20:
940–944
6. Sas DJ, Hulsey TC, Shatat IF, Orak JK (2010) Increasing incidence of
kidney stones in children evaluated in the emergency department. J
Pediatr 157:132–137
Table 5 Metabolic characteris-
tics of reference patients with hy-
peruricemia and reference pa-
tients with normouricemia
Data are presented as the median
with the IQR in parenthesis, un-
less otherwise indicated
Metabolic parameters Reference group (HU+) Reference group (HU−) p
Oxalate/cr. (mmol/g cr.) 0.23 (0.15–0.30) 0.31 (0.23–0.39) <0.01
Citrate/cr. (mg/g cr.) 501.53 (448.83–609.57) 654.69 (524.55–866.23) <0.01
Ca/cr. (mmol/g cr.) 2.50 (1.86–3.00) 3.03 (2.30–3.80) <0.01
P/cr. (mmol/g cr.) 17.22 (13.88–20.42) 21.61 (17.56–27.04) <0.01
Mg/cr. (mmol/g cr.) 2.96 (2.51–3.42) 3.65 (3.10–4.31) <0.01
Uric acid/cr. 0.37 (0.32–0.41) 0.45 (0.38–0.55) <0.01
Ca/ citrate 0.19 (0.14–0.24) 0.17 (0.12–0.24) NS
802 Pediatr Nephrol (2015) 30:797–803
7. Bush NC (2010) Epidemiological trends in pediatric urolithiasis.
Editorial comment. J Urol 184:1104–1105
8. Routh JC, Graham DA, Nelson CP (2010) Epidemiological trends in
pediatric urolithiasis at United States freestanding pediatric hospitals.
J Urol 184:1100
9. Baştuğ F, Düşünsel R (2012) Pediatric urolithiasis: causative factors,
diagnosis and medical management. Nat Rev Urol 9:138–146
10. Sarkissian A, Babloyan A, Arikyants N, Hesse A, Blau N, Leumann
E (2001) Pediatric urolithiasis in Armenia: a study of 198 patients
observed from 1991 to 1999. Pediatr Nephrol 16:728–732
11. Basaklar AC, Kale N (1991) Experience with childhood urolithiasis.
Report of 196 cases. Br J Urol 67:203–205
12. van’t Hoff WG (2004) Aetiological factors in paediatric urolithiasis.
Nephron Clin Pract 98:c45–c48
13. Cameron MA, Sakhaee K, Moe OW (2005) Nephrolithiasis in chil-
dren. Pediatr Nephrol 20:1587–1592
14. Areses Trapote R, Urbieta Garagorri MA, Ubetagoyena Arrieta M,
Mingo Monge T, Arruebarrena Lizarraga D (2004) Evaluation of
renal stone disease: metabolic study. An Pediatr (Barc) 61:418–427
15. Nicoletta JA, Lande MB (2006) Medical evaluation and treatment of
urolithiasis. Pediatr Clin North Am 53:479–491
16. Ece A, Ozdemir E, Gürkan F, Dokucu AI, Akdeniz O (2000)
Characteristics of pediatric urolithiasis in south-east Anatolia. Int J
Urol 7:330–334
17. Ozokutan BH, Küçükaydin M, Gündüz Z, Kabaklioğlu M, Okur H,
Turan C (2000) Urolithiasis in childhood. Pediatr Surg Int 16:60–63
18. Battino BS, DeFOORW, Coe F, Tackett L, Erhard M, Wacksman J,
Sheldon CA, Minevich E (2002) Metabolic evaluation of children
with urolithiasis: are adult references for supersaturation appropriate?
J Urol 168:2568–2571
19. Van Savage JG, Palanca LG, Andersen RD, Rao GS, Slaughenhoupt
BL (2000) Treatment of distal ureteral stones in children: similarities
to the American urological association guidelines in adults. J Urol
164:1089–1093
20. Taylor EN, Stampfer MJ, Curhan GC (2005) Obesity, weight gain,
and the risk of kidney stones. JAMA 293:455–462
21. Taylor EN, Stampfer MJ, Curhan GC (2005) Diabetes mellitus and
the risk of nephrolithiasis. Kidney Int 68:1230–1235
22. Madore F, Stampfer MJ, Rimm EB, Curhan GC (1998)
Nephrolithiasis and risk of hypertension. Am J Hypertens 11:46–53
23. Madore F, Stampfer MJ, Willett WC, Speizer FE, Curhan GC (1998)
Nephrolithiasis and risk of hypertension in women. Am J Kidney Dis
32:802–807
24. Tsouli SG, Liberopoulos EN, Mikhailidis DP, Athyros VG, Elisaf MS
(2006) Elevated serum uric acid levels in metabolic syndrome: an active
component or an innocent bystander? Metabolism 55:1293–1301
25. Schmidt MI, Watson RL, Duncan BB, Metcalf P, Brancati FL,
Sharrett AR, Davis CE, Heiss G (1996) Clustering of dyslipidemia,
hyperuricemia, diabetes, and hypertension and its association with
fasting insulin and central and overall obesity in a general population.
Atherosclerosis Risk in Communities Study Investigators.
Metabolism 45:699–706
26. Cole TJ, Green PJ (1992) Smoothing reference centile curves: the
LMS method and penalized likelihood. Stat Med 11:1305–1319
27. Kułaga Z, Litwin M, Grajda A, Kułaga K, Gurzkowska B, GóźdźM,
Pan H (2010) OLAF Study Oscillometric blood pressure percentiles
for Polish normal-weight school-aged children and adolescents.
Group J Hypertens 30:1942–1954
28. Srivastava T, Winston MJ, Auron A, Alon US (2009) Urine calcium/
citrate ratio in children with hypercalciuric stones. Pediatr Res
66:85–90
29. Laube N, Schneider A, Hesse A (2000) A new approach to calculate
the risk of calcium oxalate crystallization from unprepared native
urine. Urol Res 28:274–280
30. Porowski T, Mrozek P, Sidun J, Zoch-Zwierz W, Konstantynowicz J,
Kirejczyk JK,Motkowski R, Laube N (2010) Bonn Risk Index based
micromethod for assessing risk of urinary calcium oxalate stone
formation. J Urol 183:1157–1162
31. Alconcher LF, Castro C, Quintana D, Abt N, Moran L, Gonzalez L,
Cella M, Torelli M (1997) Urinary calcium excretion in healthy
school children. Pediatr Nephrol 11:186–188
32. Pak CY, Britton F, Peterson R, Ward D, Northcutt C, Breslau NA,
McGuire J, Sakhaee K, Bush S, Nicar M, Norman DA, Peters P
(1980) Ambulatory evaluation of nephrolithiasis. Classification, clin-
ical presentation and diagnostic criteria. Am J Med 69:19–30
33. Milliner DS, Murphy ME (1993) Urolithiasis in pediatric patients.
Mayo Clin Proc 68:241–248
34. Spivacow FR, Negri AL, del Valle EE, Calviño I, Zanchetta JR
(2010) Clinical and metabolic risk factor evaluation in young adults
with kidney stones. Int Urol Nephrol 42:471–475
35. Dursun I, Poyrazoglu HM, Dusunsel R, Gunduz Z, Gurgoze MK,
Demirci D, Kucukaydin M (2008) Pediatric urolithiasis: an 8-year
experience of single centre. Int Urol Nephrol 40:3–9
36. Caudarella R, Vescini F (2009) Urinary citrate and renal stone dis-
ease: the preventive role of alkali citrate treatment. Arch Int Urol
Androl 81:182–187
37. Rendina D, Mossetti G, De Filippo G, Benvenuto D, Vivona CL,
Imbroinise A, Zampa G, Ricchio S, Strazzullo P (2009) Association
between metabolic syndrome and nephrolithiasis in an inpatient
population in southern Italy: role of gender, hypertension and ab-
dominal obesity. Nephrol Dial Transplant 24:900–906
38. Semins MJ, Shore AD, Makary MA, Magnuson T, Johns R, Matlaga
BR (2010) The association of increasing bodymass index and kidney
stone disease. J Urol 183:571–575
39. Chou YH, Su CM, Li CC, Liu CC, Liu ME,WuWJ, Juan YS (2011)
Difference in urinary stone components between obese and non-
obese patients. Urol Res 39:283–287
40. Negri AL, Spivacow FR, Del Valle EE, Forrester M, Rosende G,
Pinduli I (2008) Role of overweight and obesity on the urinary
excretion of promoters and inhibitors of stone formation in stone
formers. Urol Res 36:303–307
41. Powell CR, Stoller ML, Schwartz BF, Kane C, Gentle DL, Bruce JE,
Leslie SW (2000) Impact of body weight on urinary electrolytes in
urinary stone formers. Urology 55:825–830
42. Taylor EN, Curhan GC (2006) Body size and 24-hour urine compo-
sition. Am J Kidney Dis 48:905–915
43. Maalouf NM, Sakhaee K, Parks JH, Coe FL, Adams-Huet B, Pak CY
(2004) Association of urinary pH with body weight in
nephrolithiasis. Kidney Int 65:1422–1425
44. Nouvenne A,Meschi T, Guerra A, Allegri F, Prati B, Borghi L (2008)
Role of BMI on lithogenic risk in women with idiopathic calcium
nephrolithiasis and controls. Urol Res 36:223
45. LiWM, Chou YH, Li CC, Liu CC, Huang SP,WuWJ, Chen CW, Su
CY, Lee MH, Wei YC, Huang CH (2009) Association of body mass
index and urine pH in patients with urolithiasis. Urol Res 37:193–196
46. Abate N, ChandaliaM, Cabo-ChanAV Jr,MoeOW, SakhaeeK (2004)
Themetabolic syndrome and uric acid nephrolithiasis: novel features of
renal manifestation of insulin resistance. Kidney Int 65:386–392
47. Dwyer ME, Krambeck AE, Bergstralh EJ, Milliner DS, Lieske JC,
Rule AD (2012) Temporal trends in incidence of kidney stones among
children: a 25-year population based study. J Urol 188:247–252
48. Penido MG, Srivastava T, Alon US (2013) Pediatric primary urolith-
iasis: 12-year experience at a Midwestern Children’s Hospital. J Urol
189:1493–1497
49. Kieran K, Giel DW, Morris BJ, Wan JY, Tidwell CD, Giem A,
Jerkins GR, Williams MA (2010) Pediatric urolithiasis–does body
mass index influence stone presentation and treatment? J Urol 184:
1810–1815
50. Reddy ST, Wang CY, Sakhaee K, Brinkley L, Pak CY (2002) Effect
of low-carbohydrate high-protein diets on acid–base balance, stone-
forming propensity, and calcium metabolism. Am J Kidney Dis 40:
265–274
Pediatr Nephrol (2015) 30:797–803 803
